ArticleNanomedicine (London, England)2018
Development of photoactive Sweet-C
Article in Nanomedicine (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Aminofullerenes as targeted inhibitors of EGFR: from pancreatic cancer inhibitors toNanomedicine (London, England) · 2025Article
- Fullerene Derivatives for Tumor Treatment: Mechanisms and Application.International journal of nanomedicine · 2024Review
- Putting a "CPharmaceuticals (Basel, Switzerland) · 2023Article
- Review
- Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor.International journal of nanomedicine · 2023Article
- Carbon-based glyco-nanoplatforms: towards the next generation of glycan-based multivalent probes.Chemical Society reviews · 2022Review
- Article
- Controlled Decoration of [60]Fullerene with Polymannan Analogues and Amino Acid Derivatives through Malondiamide-Based Linkers.Molecules (Basel, Switzerland) · 2022Article
- Synthesis and applications of [60]fullerene nanoconjugate with 5-aminolevulinic acid and its glycoconjugate as drug delivery vehicles.RSC advances · 2022Article
- Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives.Theranostics · 2022Review
- Multivalent Tryptophan- and Tyrosine-Containing [60]Fullerene Hexa-Adducts as Dual HIV and Enterovirus A71 Entry Inhibitors.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Recent advances in carbon nanomaterials for biomedical applications: A review.Current opinion in biomedical engineering · 2021Review
- Interactions of a Water-Soluble Glycofullerene with Glucose Transporter 1. Analysis of the Cellular Effects on a Pancreatic Tumor Model.Nanomaterials (Basel, Switzerland) · 2021Article
- Ligand-Targeted Delivery of Photosensitizers for Cancer Treatment.Molecules (Basel, Switzerland) · 2020Review
- Evaluation of the Biodistribution of Serinolamide-Derivatized CNanomaterials (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
aimGlycoconjugated C MATERIALS &
methodsHerein, we describe the synthesis and biological characterization of a hexakis-glucosamine C
resultsSynthesized fullerene derivative predominantly accumulates in the nucleus of pancreatic stellate cells; is inherently nontoxic up to concentrations of 1 mg/ml; and is photoactive when illuminated with blue and green light, allowing its use as a photodynamic therapy agent.
conclusionObtained glycoconjugated nanoplatform is a promising nanotherapeutic for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.